1315 Capital Revenue and Competitors

1315 Capital provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty therapeutics companies, the latter including businesses focused on cost containment and digital health. We believe that these investment areas are attractive largely due to numerous niche market sub-segments and business models where high-quality management teams can rapidly grow small platform companies, in a capital efficient way, into large and important businesses. The firm targets $10-$30 million investments in commercial healthcare entities that we believe have the potential to scale to approximately $100 million of revenue, a level we believe is highly attractive for acquisition or to access the public markets. In addition to experienced investing partners, 1315 Capital leverages an operating partner model of CEO and “Right Hand” COO Executive, a partnership that works together to navigate diligence, drive decisions, and seeks to achieve premium exits. Three operating teams contribute their collective experience to 1315 Capital in the areas of medical technologies, healthcare services, and specialty therapeutics. These three teams have built companies from expansion and growth phases to entities with revenues in excess of $100 million, resulting in almost $5 billion of aggregate exit value.